2024 TOPA 9th Annual Conference


Date: Nov 2, 2024 01:00 AM

Fee

$0.00

CE Hours

6.00

CE Units

0.600

Registration closes on Dec 02, 2024 01:00 AM

Activity Type

Knowledge

Target Audience(s)

Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

 

Registration start from
11/02/2024  

Although still a rare tumor type, the incidence of neuroendocrine/carcinoid tumors continues to grow. The management of these patients includes medical oncology, radiation oncology, surgery, and interventional radiology. There have been recent advancements in the treatment of carcinoid tumors, including radioligand therapy such as lutetium-177. Knowledge of the treatments used in carcinoid tumors is crucial for pharmacists to know to help manage unique toxicities these patients might experience. The purpose of this knowledge-based activity is to review the basics of carcinoid tumors and the treatments used, as well as their toxicities.

Objectives

  • Recognize different types of carcinoid tumors and their disease pathology
  • Identify common treatment regimens used and carcinoid tumors
  • Describe side effect management of treatment regimens used in carcinoid tumors

Speaker(s)/Author(s)

Amanda Cass

Activity Number

0064-9999-24-220-L01-P
Date: 11/02/24
Time: 01:00 AM - 01:00 AM

CE Hours

0.50
Registration start from
11/02/2024  

Registration start from
11/02/2024  

Clinical data regarding the use of ctDNA is solid tumors is rapidly growing. As part of the multidisciplinary healthcare team, oncology pharmacists need to be able to respond to drug utilization questions related to ctDNA findings. Currently, pharmacists may lack knowledge about ctDNA, including biologic characteristics and clinical data. With further education, pharmacists can play a key role in educating patients and other healthcare professionals about this topic. The purpose of this presentation is to define ctDNA, describe strengths and limitations of using ctDNA as a cancer biomarker, and to discuss applications of ctDNA for detecting minimal residual disease in solid tumors.

Objectives

  • Define circulating tumor DNA (ctDNA)
  • Describe strengths and limitations of utilizing ctDNA as a cancer biomarker
  • Discuss applications of ctDNA for detecting minimal residual disease in solid tumors

Speaker(s)/Author(s)

Sarah Cimino

Activity Number

0064-9999-24-221-L01-P
Date: 11/02/24
Time: 01:00 AM - 01:00 AM

CE Hours

0.50
Registration start from
11/02/2024  

Registration start from
11/02/2024  

The management of non-small cell lung cancer (NSCLC) has drastically changed in the last decade with the introduction of immune checkpoint inhibitors (ICI). With the publication of Keynote 189, chemo-immunotherapy has become standard of care for the treatment of metastatic NSCLC. Durvalumab maintenance therapy then showed a benefit in the early stage, unresectable setting. Pembrolizumab and atezolizumab maintenance after resection also showed an improvement in disease-free survival. Nivolumab is currently recommended in the National Comprehensive Cancer Network (NCCN) guidelines in the neoadjuvant setting, while pembrolizumab is currently the only ICI recommended for perioperative therapy. With the recent publications of perioperative nivolumab and durvalumab, the landscape of the guidelines is likely to change. It is imperative for pharmacists to be aware of this emerging data and where these ICI might be best utilized in patient care. This session will aim to discuss the data behind each ICI in the perioperative setting, and the nuances in each trial design in order to select the optimal regimen for patients.

Objectives

  • Review the evidence behind perioperative immune checkpoint inhibitors for early stage non-small cell lung cancer
  • Discuss a treatment plan incorporating perioperative immune checkpoint inhibitors for appropriate patients

Speaker(s)/Author(s)

Kori Holman-Daniels

Activity Number

0064-9999-24-222-L01-P
Date: 11/02/24
Time: 01:00 AM - 01:00 AM

CE Hours

0.50
Registration start from
11/02/2024  

Registration start from
11/02/2024  

AML and MDS both have novel agents and expanded indications for their management. Recent data has offered an insight into use in the newly-diagnosed and relapsed/refractory setting and in both patients who are fit or unfit for aggressive chemotherapy (in the case of AML). Given the expansion of decision pathways in recent years, it is important for pharmacists to be aware of when to recommend and avoid particular agents, and how to properly care for patients receiving these agents. The purpose of this knowledge-based activity is to analyze recent trial data for novel therapies in AML & MDS to delineate the benefit, or lack thereof, given to patients.

Objectives

  • Review novel and expanded indication medications for AML & MDS
  • Compare trial data for medications used in AML/MDS
  • Discuss novel adverse effects associated with new therapies
  • Select treatment plans for patient cases based on the data reviewed

Speaker(s)/Author(s)

Dennis Marjoncu, PharmD, BCOP
Clinical Pharmacy Specialist- Hematopoietic Cell Transplantation, Methodist University Hospital

Activity Number

0064-9999-24-223-L01-P
Date: 11/02/24
Time: 01:00 AM - 01:00 AM

CE Hours

1.00
Registration start from
11/02/2024  

Registration start from
11/02/2024  

An educational presentation on early stage melanoma treatment is urgently needed to equip oncology pharmacists with the necessary knowledge and skills. This will ensure they can provide the highest standard of care, keeping pace with the latest therapeutic advancements, and ultimately improving patient outcomes in the fight against melanoma.

Objectives

  • Recall the efficacy, dosing, and safety of current and emerging therapies for early stage melanoma
  • Identify strategies to personalize treatment based on patient-specific factors to select the most appropriate therapy for early stage melanoma

Speaker(s)/Author(s)

Colleen McCabe

Activity Number

0064-9999-24-224-L01-P
Date: 11/02/24
Time: 01:00 AM - 01:00 AM

CE Hours

0.50
Registration start from
11/02/2024  

Registration start from
11/02/2024  

The treatment landscape of early stage and metastatic breast cancer has evolved significantly over the last 2 years with new literature support regarding not only targeted therapies, but also sequencing and appropriate use, as not all patients benefit. Understanding current evidence based practices within this evolving space and impact on clinical decision making as well as patient specific factors that make patients eligible is essential. Additionally, with new, targeted therapies, AE profiles are more complex and require a higher level of monitoring and AE management to improve adherence and continuation. The purpose of this knowledge-based activity is to review the most recent updates in breast cancer systemic therapies and emphasize the role of the pharmacist.

Objectives

  • Review the current literature for the utilization of adjuvant CDK4/6 inhibitors in HR+, HER2- early stage breast cancer and understand the differences between abemaciclib and ribociclib usage
  • Describe the evolving treatment landscape of HR+, HER2- metastatic breast cancer with the integration of more targeted therapies such as oral SERDs and AKT inhibitors and impact on treatment paradigm
  • Explain the concept of "HER2 low" and ??ultra-low????and use of trastuzumab deruxtecan within metastatic HER2- breast cancer

Speaker(s)/Author(s)

Heather Moore

Activity Number

0064-9999-24-225-L01-P
Date: 11/02/24
Time: 01:00 AM - 01:00 AM

CE Hours

1.00
Registration start from
11/02/2024  

Registration start from
11/02/2024  

The use of psychometric tests and frameworks, specifically personality tests like the DISC (Dominance, Influence, Steadiness, Conscientiousness) framework, have been used in various health professions as a tool for team building, communication, leadership, conflict resolution, and career advancement. The identification and understanding of personality types and behavioral characteristics of oneself and others based on psychometric tests and frameworks (i.e., DISC) could improve communication and overall interactions between healthcare providers and their patients. As a vital member of the healthcare team, pharmacist may lack knowledge regarding the impact of these personality types and behavioral characteristics (i.e., DISC framework) on their daily interactions with oncology patients, negatively impacting their ability for rapport-building, communication, and motivation. The purpose of this knowledge-based activity is to describe and compare individual personality types, using the DISC framework, and identify techniques of navigating them to positively impact rapport-building, communication, and motivation of pharmacist-patient interactions within oncology practice.

Objectives

  • Describe the DISC (Dominance, Influence, Steadiness, Conscientiousness) framework and its relevance to pharmacist-patient interactions within oncology practice
  • Compare the four primary behavioral styles within the DISC framework and their potential implications for communication with oncology patients
  • Review practical strategies for adapting pharmacist-patient communication approaches based on the unique personality traits and communication preferences of oncology patients
  • Identify active listening techniques to enhance empathy and rapport-building within encounters with oncology patients through utilization of the DISC framework

Speaker(s)/Author(s)

Gregory Sneed, PharmD
Assistant Professor, UTHSC College of Pharmacy

Activity Number

0064-9999-24-226-L01-P
Date: 11/02/24
Time: 01:00 AM - 01:00 AM

CE Hours

1.00
Registration start from
11/02/2024  

Registration start from
11/02/2024  

Studies confirm continued presence of hazardous drug contamination in healthcare facilities propounding the need for hazardous drug handling safeguards.  The establishment of USP 800 for the safe handling of hazardous drugs has been long-awaited and fraught with delays and enforceability changes.  USP 800 in conjunction with the updated 797 guidelines pose operational challenges to meet their requirements.  The purpose of this activity is to provide a big picture and granular review of the status of USP 800 enforceability and the barriers and possible solutions in endeavoring to comply with these directives.

Objectives

  • Review the history and scope of the hazardous drug standards
  • Describe the existing requirements and best practices for the current hazardous drug handling standards
  • Cite potential barriers and solutions for the safe handling of hazardous drugs

Speaker(s)/Author(s)

Beatrice Turner, PharmD, BCPS
Erlanger Health System

Activity Number

0064-9999-24-227-L01-P
Date: 11/02/24
Time: 01:00 AM - 01:00 AM

CE Hours

1.00
Registration start from
11/02/2024